ReviewDrug design, development and therapy2026
Advances of Peptide-Drug Conjugates in the Treatment of Digestive System Tumors.
Review in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digestive system tumors, including gastric cancer, hepatocellular carcinoma, pancreatic cancer, and colorectal cancer, represent one of the most prevalent and lethal malignancy groups worldwide, with high incidence and mortality rates. Despite the continuous development of chemotherapy in cancer treatment, this traditional therapy generally suffers from insufficient tumor specificity, drug resistance and limited efficacy. Precise targeting strategies such as antibody-drug conjugates (ADCs) and peptide-drug conjugates (PDCs) combine cell-targeting delivery with potent antitumor activity and have demonstrated therapeutic potential in digestive system tumors. Compared with ADCs, PDCs offer advantages such as lower molecular weight, improved tumor penetration and reduced immunogenicity risk. Preclinical studies suggest that PDCs can enhance tumor-specific drug accumulation and reduce damage to normal tissues, which may compensate for the shortcomings of traditional chemotherapy. In this review, we systematically outline recent progress in PDC research for digestive system tumors, focusing on target selection and PDC design strategies. Representative PDCs targeting integrins, GPC3, EGFR, HER2, transferrin receptor, and VEGFR in digestive system tumors are highlighted. Based on the preclinical findings and early clinical results, we provide insights on future directions for PDC treatment in digestive system tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.